tiprankstipranks
Trending News
More News >
Divi's Laboratories Limited (IN:DIVISLAB)
:DIVISLAB
India Market

Divi's Laboratories Limited (DIVISLAB) Stock Forecast & Price Target

Compare
1 Followers
See the Price Targets and Ratings of:

DIVISLAB Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Divi's
Laboratories Limited
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DIVISLAB Stock 12 Month Forecast

Average Price Target

₹6,641.67
▲(5.74%Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Divi's Laboratories Limited in the last 3 months. The average price target is ₹6,641.67 with a high forecast of ₹7,400.00 and a low forecast of ₹5,475.00. The average price target represents a 5.74% change from the last price of ₹6,281.35.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4282":"₹4,282","7401":"₹7,401","5061.75":"₹5,061.8","5841.5":"₹5,841.5","6621.25":"₹6,621.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7400,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6641.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹7K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5475,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹5.47K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4282,5061.75,5841.5,6621.25,7401],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6086.15,6187.215384615384,6288.280769230769,6389.346153846153,6490.411538461538,6591.4769230769225,6692.542307692307,6793.607692307693,6894.673076923077,6995.738461538462,7096.803846153846,7197.869230769231,7298.934615384615,{"y":7400,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6086.15,6128.882307692307,6171.614615384615,6214.346923076922,6257.079230769231,6299.8115384615385,6342.543846153846,6385.276153846154,6428.008461538461,6470.740769230769,6513.473076923077,6556.205384615385,6598.9376923076925,{"y":6641.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6086.15,6039.138461538461,5992.126923076923,5945.115384615385,5898.103846153846,5851.092307692307,5804.080769230769,5757.069230769231,5710.057692307692,5663.046153846154,5616.034615384615,5569.023076923077,5522.011538461538,{"y":5475,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4283.68,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4571.86,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":4891.6,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5036.35,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5423.8,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":5893.9,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6250.2,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":6250.2,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6070.95,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5575.9,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5477.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5548.5,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6086.15,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target₹7,400Average Price Target₹6,642Lowest Price Target₹5,475
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
₹6,850₹7,050
Buy
12.24%
Upside
Reiterated
04/25/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,050 at CitiCiti analyst Vivek Agrawal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,050.00 (from INR6,850.00) while maintaining a Buy rating.
Goldman Sachs Analyst forecast on IN:DIVISLAB
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹5,325₹5,475
Hold
-12.84%
Downside
Reiterated
04/18/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR5,475 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR5,475.00 (from INR5,325.00) while maintaining a Neutral rating.
Macquarie
₹7,400
Buy
17.81%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Divi's Laboratories Ltd (DIVI:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR7,400.00 price target on Divi's Laboratories Ltd (DIVI:IN).
HSBC
₹5,425
Sell
-13.63%
Downside
Reiterated
02/04/25
HSBC Reiterates Reduce Rating on Divi\'s Laboratories Ltd (DIVI:IN)HSBC analyst Damayanti Kerai reiterated a Reduce rating and INR5,425.00 price target on Divi\'s Laboratories Ltd (DIVI:IN).
Jefferies Analyst forecast on IN:DIVISLAB
Alok DalalJefferies
Jefferies
₹5,790₹6,280
Hold
-0.02%
Downside
Reiterated
01/10/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR6,280 at JefferiesJefferies analyst Alok Dalal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR6,280.00 (from INR5,790.00) while maintaining a Hold rating.
Kotak Mahindra Analyst forecast on IN:DIVISLAB
Alankar GarudeKotak Mahindra
Kotak Mahindra
₹4,000
Sell
-36.32%
Downside
Reiterated
12/27/24
Kotak Reiterates Sell (4) Rating on Divi's Laboratories Ltd (DIVI:IN)Kotak analyst Alankar Garude reiterated a Sell (4) rating and INR4,000.00 price target on Divi's Laboratories Ltd (DIVI:IN).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Citi
₹6,850₹7,050
Buy
12.24%
Upside
Reiterated
04/25/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR7,050 at CitiCiti analyst Vivek Agrawal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR7,050.00 (from INR6,850.00) while maintaining a Buy rating.
Goldman Sachs Analyst forecast on IN:DIVISLAB
Shyam SrinivasanGoldman Sachs
Goldman Sachs
₹5,325₹5,475
Hold
-12.84%
Downside
Reiterated
04/18/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR5,475 at Goldman SachsGoldman Sachs analyst Shyam Srinivasan raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR5,475.00 (from INR5,325.00) while maintaining a Neutral rating.
Macquarie
₹7,400
Buy
17.81%
Upside
Reiterated
03/28/25
Macquarie Reiterates Outperform Rating on Divi's Laboratories Ltd (DIVI:IN)Macquarie analyst Kunal Dhamesha reiterated an Outperform rating and INR7,400.00 price target on Divi's Laboratories Ltd (DIVI:IN).
HSBC
₹5,425
Sell
-13.63%
Downside
Reiterated
02/04/25
HSBC Reiterates Reduce Rating on Divi\'s Laboratories Ltd (DIVI:IN)HSBC analyst Damayanti Kerai reiterated a Reduce rating and INR5,425.00 price target on Divi\'s Laboratories Ltd (DIVI:IN).
Jefferies Analyst forecast on IN:DIVISLAB
Alok DalalJefferies
Jefferies
₹5,790₹6,280
Hold
-0.02%
Downside
Reiterated
01/10/25
Divi's Laboratories Ltd (DIVI:IN) PT Raised to INR6,280 at JefferiesJefferies analyst Alok Dalal raised the price target on Divi's Laboratories Ltd (DIVI:IN) to INR6,280.00 (from INR5,790.00) while maintaining a Hold rating.
Kotak Mahindra Analyst forecast on IN:DIVISLAB
Alankar GarudeKotak Mahindra
Kotak Mahindra
₹4,000
Sell
-36.32%
Downside
Reiterated
12/27/24
Kotak Reiterates Sell (4) Rating on Divi's Laboratories Ltd (DIVI:IN)Kotak analyst Alankar Garude reiterated a Sell (4) rating and INR4,000.00 price target on Divi's Laboratories Ltd (DIVI:IN).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Divi's Laboratories Limited

1 Month
xxx
Success Rate
1/2 ratings generated profit
50%
Average Return
+3.50%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +3.50% per trade.
3 Months
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+12.05%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +12.05% per trade.
1 Year
Success Rate
2/2 ratings generated profit
100%
Average Return
+11.60%
reiterated a buy rating 2 months ago
Copying Kunal Dhamesha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +11.60% per trade.
2 Years
xxx
Success Rate
2/2 ratings generated profit
100%
Average Return
+11.60%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +11.60% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DIVISLAB Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
0
0
0
0
Buy
0
1
2
3
4
Hold
2
2
3
2
2
Sell
1
2
1
1
0
Strong Sell
0
0
0
0
0
total
3
5
6
6
6
In the current month, DIVISLAB has received 4 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DIVISLAB average Analyst price target in the past 3 months is 6,641.67.
Each month's total comprises the sum of three months' worth of ratings.

DIVISLAB Financial Forecast

DIVISLAB Earnings Forecast

Next quarter’s earnings estimate for DIVISLAB is ₹21.26 with a range of ₹19.65 to ₹22.43. The previous quarter’s EPS was ₹24.90. DIVISLAB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.13% of the time in the same period. In the last calendar year DIVISLAB has Outperformed its overall industry.
Next quarter’s earnings estimate for DIVISLAB is ₹21.26 with a range of ₹19.65 to ₹22.43. The previous quarter’s EPS was ₹24.90. DIVISLAB beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 39.13% of the time in the same period. In the last calendar year DIVISLAB has Outperformed its overall industry.

DIVISLAB Sales Forecast

Next quarter’s sales forecast for DIVISLAB is ₹24.99B with a range of ₹24.79B to ₹25.20B. The previous quarter’s sales results were ₹25.85B. DIVISLAB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 40.81% of the time in the same period. In the last calendar year DIVISLAB has Outperformed its overall industry.
Next quarter’s sales forecast for DIVISLAB is ₹24.99B with a range of ₹24.79B to ₹25.20B. The previous quarter’s sales results were ₹25.85B. DIVISLAB beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 40.81% of the time in the same period. In the last calendar year DIVISLAB has Outperformed its overall industry.

DIVISLAB Stock Forecast FAQ

What is IN:DIVISLAB’s average 12-month price target, according to analysts?
Based on analyst ratings, Divi's Laboratories Limited’s 12-month average price target is 6,641.67.
    What is IN:DIVISLAB’s upside potential, based on the analysts’ average price target?
    Divi's Laboratories Limited has 5.74% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Divi's Laboratories Limited a Buy, Sell or Hold?
          Divi's Laboratories Limited has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Divi's Laboratories Limited’s share price target?
            The average share price target for Divi's Laboratories Limited is 6,641.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is ₹7,400.00 ,and the lowest forecast is ₹5,475.00. The average share price target represents 5.74% Increase from the current price of ₹6,281.35.
              What do analysts say about Divi's Laboratories Limited?
              Divi's Laboratories Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Divi's Laboratories Limited?
                To buy shares of IN:DIVISLAB, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis